TargetCancer Foundation implemented Medrio’s remote consent function in their TCF-001 TRACK study, which has an objective to determine if rare tumors can benefit from matched molecular therapy. The study is remotely enrolling a total of 400 patients in the United States using electronic informed consent.
TargetCancer Foundation Successfully Engages and Empowers Rare Cancer Patients with Medrio
- Success Story
- DCT, eConsent
Subscribe to our mailing list
Sign up to have our latest insights delivered to your inbox.
